Listed

Rocket Pharmaceuticals, Inc.

RCKTNasdaqCIK 1281895HealthcareFiscal year ends Dec 31

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Revenue$0, Q2 FY2026
Operating income−$46.9m, Q2 FY2026
Net income$123.2m, Q2 FY2026
Rocket Pharmaceuticals, Inc., income statement, quarterly
Line itemUnitQ3 FY20232023-09-30Q4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Revenue$m0.0Revenue, Q3 FY2023, three months to 2023-09-30$0. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2024-11-07, accession 0000950170-24-123459.Report this figure0.0Revenue, Q4 FY2023, three months to 2023-12-31$0. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-02-27, accession 0000950170-25-029002. Derived: 12-month figure less the 9-month figure.Report this figure0.0Revenue, Q1 FY2024, three months to 2024-03-31$0. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-05-08, accession 0000950170-25-066898.Report this figure0.0Revenue, Q2 FY2024, three months to 2024-06-30$0. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-08-07, accession 0000950170-25-104996.Report this figure0.0Revenue, Q3 FY2024, three months to 2024-09-30$0. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-06, accession 0001193125-25-269474.Report this figure0.0Revenue, Q4 FY2024, three months to 2024-12-31$0. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001193125-26-076551. Derived: 12-month figure less the 9-month figure.Report this figure0.0Revenue, Q1 FY2025, three months to 2025-03-31$0. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-07, accession 0001193125-26-211873.Report this figure0.0Revenue, Q2 FY2025, three months to 2025-06-30$0. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-10, accession 0001193125-26-342348.Report this figure0.0Revenue, Q3 FY2025, three months to 2025-09-30$0. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-06, accession 0001193125-25-269474.Report this figure0.0Revenue, Q4 FY2025, three months to 2025-12-31$0. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001193125-26-076551. Derived: 12-month figure less the 9-month figure.Report this figure0.0Revenue, Q1 FY2026, three months to 2026-03-31$0. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-07, accession 0001193125-26-211873.Report this figure0.0Revenue, Q2 FY2026, three months to 2026-06-30$0. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-10, accession 0001193125-26-342348.Report this figure
Research and development$m46.8Research and development, Q3 FY2023, three months to 2023-09-30$46.8m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2024-11-07, accession 0000950170-24-123459.Report this figure41.7Research and development, Q4 FY2023, three months to 2023-12-31$41.7m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2025-02-27, accession 0000950170-25-029002. Derived: 12-month figure less the 9-month figure.Report this figure45.2Research and development, Q1 FY2024, three months to 2024-03-31$45.2m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-05-08, accession 0000950170-25-066898.Report this figure46.3Research and development, Q2 FY2024, three months to 2024-06-30$46.3m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-08-07, accession 0000950170-25-104996.Report this figure42.3Research and development, Q3 FY2024, three months to 2024-09-30$42.3m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-11-06, accession 0001193125-25-269474.Report this figure37.4Research and development, Q4 FY2024, three months to 2024-12-31$37.4m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-02-26, accession 0001193125-26-076551. Derived: 12-month figure less the 9-month figure.Report this figure35.9Research and development, Q1 FY2025, three months to 2025-03-31$35.9m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-05-07, accession 0001193125-26-211873.Report this figure42.7Research and development, Q2 FY2025, three months to 2025-06-30$42.7m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-08-10, accession 0001193125-26-342348.Report this figure34.1Research and development, Q3 FY2025, three months to 2025-09-30$34.1m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-11-06, accession 0001193125-25-269474.Report this figure29.3Research and development, Q4 FY2025, three months to 2025-12-31$29.3m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-02-26, accession 0001193125-26-076551. Derived: 12-month figure less the 9-month figure.Report this figure31.5Research and development, Q1 FY2026, three months to 2026-03-31$31.5m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-05-07, accession 0001193125-26-211873.Report this figure29.5Research and development, Q2 FY2026, three months to 2026-06-30$29.5m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-08-10, accession 0001193125-26-342348.Report this figure
Operating income$m(65.4)Operating income, Q3 FY2023, three months to 2023-09-30−$65.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2024-11-07, accession 0000950170-24-123459.Report this figure(63.3)Operating income, Q4 FY2023, three months to 2023-12-31−$63.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2025-02-27, accession 0000950170-25-029002. Derived: 12-month figure less the 9-month figure.Report this figure(67.4)Operating income, Q1 FY2024, three months to 2024-03-31−$67.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-05-08, accession 0000950170-25-066898.Report this figure(73.7)Operating income, Q2 FY2024, three months to 2024-06-30−$73.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-08-07, accession 0000950170-25-104996.Report this figure(69.4)Operating income, Q3 FY2024, three months to 2024-09-30−$69.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-06, accession 0001193125-25-269474.Report this figure(62.7)Operating income, Q4 FY2024, three months to 2024-12-31−$62.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-26, accession 0001193125-26-076551. Derived: 12-month figure less the 9-month figure.Report this figure(64.4)Operating income, Q1 FY2025, three months to 2025-03-31−$64.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-07, accession 0001193125-26-211873.Report this figure(71.1)Operating income, Q2 FY2025, three months to 2025-06-30−$71.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-10, accession 0001193125-26-342348.Report this figure(52.2)Operating income, Q3 FY2025, three months to 2025-09-30−$52.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-06, accession 0001193125-25-269474.Report this figure(44.0)Operating income, Q4 FY2025, three months to 2025-12-31−$44.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-26, accession 0001193125-26-076551. Derived: 12-month figure less the 9-month figure.Report this figure(48.5)Operating income, Q1 FY2026, three months to 2026-03-31−$48.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-07, accession 0001193125-26-211873.Report this figure(46.9)Operating income, Q2 FY2026, three months to 2026-06-30−$46.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-10, accession 0001193125-26-342348.Report this figure
Interest expense$m0.5Interest expense, Q3 FY2023, three months to 2023-09-30$469.0k. XBRL concept us-gaap:InterestExpense. 10-Q filed 2024-11-07, accession 0000950170-24-123459.Report this figure0.5Interest expense, Q4 FY2023, three months to 2023-12-31$470.0k. XBRL concept us-gaap:InterestExpense. 10-K filed 2025-02-27, accession 0000950170-25-029002. Derived: 12-month figure less the 9-month figure.Report this figure0.5Interest expense, Q1 FY2024, three months to 2024-03-31$471.0k. XBRL concept us-gaap:InterestExpense. 10-Q filed 2025-05-08, accession 0000950170-25-066898.Report this figure0.5Interest expense, Q2 FY2024, three months to 2024-06-30$471.0k. XBRL concept us-gaap:InterestExpense. 10-Q filed 2025-08-07, accession 0000950170-25-104996.Report this figure0.5Interest expense, Q3 FY2024, three months to 2024-09-30$471.0k. XBRL concept us-gaap:InterestExpense. 10-Q filed 2025-11-06, accession 0001193125-25-269474.Report this figure0.5Interest expense, Q4 FY2024, three months to 2024-12-31$473.0k. XBRL concept us-gaap:InterestExpense. 10-K filed 2026-02-26, accession 0001193125-26-076551. Derived: 12-month figure less the 9-month figure.Report this figure0.5Interest expense, Q1 FY2025, three months to 2025-03-31$472.0k. XBRL concept us-gaap:InterestExpense. 10-Q filed 2026-05-07, accession 0001193125-26-211873.Report this figure0.5Interest expense, Q2 FY2025, three months to 2025-06-30$473.0k. XBRL concept us-gaap:InterestExpense. 10-Q filed 2026-08-10, accession 0001193125-26-342348.Report this figure0.5Interest expense, Q3 FY2025, three months to 2025-09-30$473.0k. XBRL concept us-gaap:InterestExpense. 10-Q filed 2025-11-06, accession 0001193125-25-269474.Report this figure0.5Interest expense, Q4 FY2025, three months to 2025-12-31$473.0k. XBRL concept us-gaap:InterestExpense. 10-K filed 2026-02-26, accession 0001193125-26-076551. Derived: 12-month figure less the 9-month figure.Report this figure0.5Interest expense, Q1 FY2026, three months to 2026-03-31$473.0k. XBRL concept us-gaap:InterestExpense. 10-Q filed 2026-05-07, accession 0001193125-26-211873.Report this figure0.5Interest expense, Q2 FY2026, three months to 2026-06-30$473.0k. XBRL concept us-gaap:InterestExpense. 10-Q filed 2026-08-10, accession 0001193125-26-342348.Report this figure
Income tax$mnot reportednot reportednot reportednot reportednot reportednot reportednot reported0.0Income tax, Q2 FY2025, three months to 2025-06-30$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2026-08-10, accession 0001193125-26-342348.Report this figurenot reportednot reportednot reported8.6Income tax, Q2 FY2026, three months to 2026-06-30$8.6m. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2026-08-10, accession 0001193125-26-342348.Report this figure
Net income$m(61.9)Net income, Q3 FY2023, three months to 2023-09-30−$61.9m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2024-11-07, accession 0000950170-24-123459.Report this figure(59.7)Net income, Q4 FY2023, three months to 2023-12-31−$59.7m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2025-02-27, accession 0000950170-25-029002. Derived: 12-month figure less the 9-month figure.Report this figure(62.1)Net income, Q1 FY2024, three months to 2024-03-31−$62.1m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-06, accession 0001193125-25-269474.Report this figure(69.6)Net income, Q2 FY2024, three months to 2024-06-30−$69.6m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-06, accession 0001193125-25-269474.Report this figure(66.7)Net income, Q3 FY2024, three months to 2024-09-30−$66.7m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-06, accession 0001193125-25-269474.Report this figure(60.3)Net income, Q4 FY2024, three months to 2024-12-31−$60.3m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-26, accession 0001193125-26-076551. Derived: 12-month figure less the 9-month figure.Report this figure(61.3)Net income, Q1 FY2025, three months to 2025-03-31−$61.3m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-10, accession 0001193125-26-342348.Report this figure(68.9)Net income, Q2 FY2025, three months to 2025-06-30−$68.9m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-10, accession 0001193125-26-342348.Report this figure(50.3)Net income, Q3 FY2025, three months to 2025-09-30−$50.3m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-06, accession 0001193125-25-269474.Report this figure(42.5)Net income, Q4 FY2025, three months to 2025-12-31−$42.5m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-26, accession 0001193125-26-076551. Derived: 12-month figure less the 9-month figure.Report this figure(47.6)Net income, Q1 FY2026, three months to 2026-03-31−$47.6m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-10, accession 0001193125-26-342348.Report this figure123Net income, Q2 FY2026, three months to 2026-06-30$123.2m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-10, accession 0001193125-26-342348.Report this figure
Diluted EPS$ per share(0.75)Diluted EPS, Q3 FY2023, three months to 2023-09-30−$0.75 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2024-11-07, accession 0000950170-24-123459.Report this figurenot reported(0.66)Diluted EPS, Q1 FY2024, three months to 2024-03-31−$0.66 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-05-08, accession 0000950170-25-066898.Report this figure(0.74)Diluted EPS, Q2 FY2024, three months to 2024-06-30−$0.74 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-08-07, accession 0000950170-25-104996.Report this figure(0.71)Diluted EPS, Q3 FY2024, three months to 2024-09-30−$0.71 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-06, accession 0001193125-25-269474.Report this figurenot reported(0.56)Diluted EPS, Q1 FY2025, three months to 2025-03-31−$0.56 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-07, accession 0001193125-26-211873.Report this figure(0.62)Diluted EPS, Q2 FY2025, three months to 2025-06-30−$0.62 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-10, accession 0001193125-26-342348.Report this figure(0.45)Diluted EPS, Q3 FY2025, three months to 2025-09-30−$0.45 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-06, accession 0001193125-25-269474.Report this figurenot reported(0.42)Diluted EPS, Q1 FY2026, three months to 2026-03-31−$0.42 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-07, accession 0001193125-26-211873.Report this figure1.08Diluted EPS, Q2 FY2026, three months to 2026-06-30$1.08 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-10, accession 0001193125-26-342348.Report this figure
Basic EPS$ per share(0.75)Basic EPS, Q3 FY2023, three months to 2023-09-30−$0.75 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2024-11-07, accession 0000950170-24-123459.Report this figurenot reported(0.66)Basic EPS, Q1 FY2024, three months to 2024-03-31−$0.66 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-05-08, accession 0000950170-25-066898.Report this figure(0.74)Basic EPS, Q2 FY2024, three months to 2024-06-30−$0.74 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-08-07, accession 0000950170-25-104996.Report this figure(0.71)Basic EPS, Q3 FY2024, three months to 2024-09-30−$0.71 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-11-06, accession 0001193125-25-269474.Report this figurenot reported(0.56)Basic EPS, Q1 FY2025, three months to 2025-03-31−$0.56 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-07, accession 0001193125-26-211873.Report this figure(0.62)Basic EPS, Q2 FY2025, three months to 2025-06-30−$0.62 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-10, accession 0001193125-26-342348.Report this figure(0.45)Basic EPS, Q3 FY2025, three months to 2025-09-30−$0.45 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-11-06, accession 0001193125-25-269474.Report this figurenot reported(0.42)Basic EPS, Q1 FY2026, three months to 2026-03-31−$0.42 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-07, accession 0001193125-26-211873.Report this figure1.09Basic EPS, Q2 FY2026, three months to 2026-06-30$1.09 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-10, accession 0001193125-26-342348.Report this figure

Balance sheet

Cash and equivalents$224.5m, Q2 FY2026
Shareholders' equity$368.8m, Q2 FY2026
Rocket Pharmaceuticals, Inc., balance sheet, quarterly
Line itemUnitQ3 FY20232023-09-30FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Cash and equivalents$m226Cash and equivalents, Q3 FY2023, at 2023-09-30$225.7m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2023-11-07, accession 0000950170-23-060339.Report this figure55.9Cash and equivalents, FY2023, at 2023-12-31$55.9m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2025-02-27, accession 0000950170-25-029002.Report this figure35.3Cash and equivalents, Q1 FY2024, at 2024-03-31$35.3m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-05-07, accession 0000950170-24-054465.Report this figure38.6Cash and equivalents, Q2 FY2024, at 2024-06-30$38.6m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-08-06, accession 0000950170-24-091838.Report this figure65.6Cash and equivalents, Q3 FY2024, at 2024-09-30$65.6m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-11-07, accession 0000950170-24-123459.Report this figure164Cash and equivalents, FY2024, at 2024-12-31$163.6m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2026-02-26, accession 0001193125-26-076551.Report this figure49.8Cash and equivalents, Q1 FY2025, at 2025-03-31$49.8m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-05-08, accession 0000950170-25-066898.Report this figure32.8Cash and equivalents, Q2 FY2025, at 2025-06-30$32.8m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-08-07, accession 0000950170-25-104996.Report this figure75.9Cash and equivalents, Q3 FY2025, at 2025-09-30$75.9m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-11-06, accession 0001193125-25-269474.Report this figure77.6Cash and equivalents, FY2025, at 2025-12-31$77.6m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-10, accession 0001193125-26-342348.Report this figure49.6Cash and equivalents, Q1 FY2026, at 2026-03-31$49.6m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-05-07, accession 0001193125-26-211873.Report this figure225Cash and equivalents, Q2 FY2026, at 2026-06-30$224.5m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-10, accession 0001193125-26-342348.Report this figure
Current assets$m447Current assets, Q3 FY2023, at 2023-09-30$446.9m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2023-11-07, accession 0000950170-23-060339.Report this figure378Current assets, FY2023, at 2023-12-31$378.2m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2025-02-27, accession 0000950170-25-029002.Report this figure345Current assets, Q1 FY2024, at 2024-03-31$345.2m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-05-07, accession 0000950170-24-054465.Report this figure293Current assets, Q2 FY2024, at 2024-06-30$292.7m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-08-06, accession 0000950170-24-091838.Report this figure242Current assets, Q3 FY2024, at 2024-09-30$241.8m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-11-07, accession 0000950170-24-123459.Report this figure378Current assets, FY2024, at 2024-12-31$378.2m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2026-02-26, accession 0001193125-26-076551.Report this figure324Current assets, Q1 FY2025, at 2025-03-31$324.5m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-05-08, accession 0000950170-25-066898.Report this figure277Current assets, Q2 FY2025, at 2025-06-30$277.2m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-08-07, accession 0000950170-25-104996.Report this figure228Current assets, Q3 FY2025, at 2025-09-30$227.7m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-11-06, accession 0001193125-25-269474.Report this figure193Current assets, FY2025, at 2025-12-31$192.7m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-10, accession 0001193125-26-342348.Report this figure150Current assets, Q1 FY2026, at 2026-03-31$149.8m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-05-07, accession 0001193125-26-211873.Report this figure290Current assets, Q2 FY2026, at 2026-06-30$289.6m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-10, accession 0001193125-26-342348.Report this figure
Total assets$m599Total assets, Q3 FY2023, at 2023-09-30$598.8m. XBRL concept us-gaap:Assets. 10-Q filed 2023-11-07, accession 0000950170-23-060339.Report this figure566Total assets, FY2023, at 2023-12-31$566.3m. XBRL concept us-gaap:Assets. 10-K filed 2025-02-27, accession 0000950170-25-029002.Report this figure499Total assets, Q1 FY2024, at 2024-03-31$499.4m. XBRL concept us-gaap:Assets. 10-Q filed 2024-05-07, accession 0000950170-24-054465.Report this figure446Total assets, Q2 FY2024, at 2024-06-30$446.4m. XBRL concept us-gaap:Assets. 10-Q filed 2024-08-06, accession 0000950170-24-091838.Report this figure394Total assets, Q3 FY2024, at 2024-09-30$393.7m. XBRL concept us-gaap:Assets. 10-Q filed 2024-11-07, accession 0000950170-24-123459.Report this figure528Total assets, FY2024, at 2024-12-31$527.7m. XBRL concept us-gaap:Assets. 10-K filed 2026-02-26, accession 0001193125-26-076551.Report this figure471Total assets, Q1 FY2025, at 2025-03-31$471.1m. XBRL concept us-gaap:Assets. 10-Q filed 2025-05-08, accession 0000950170-25-066898.Report this figure421Total assets, Q2 FY2025, at 2025-06-30$421.0m. XBRL concept us-gaap:Assets. 10-Q filed 2025-08-07, accession 0000950170-25-104996.Report this figure368Total assets, Q3 FY2025, at 2025-09-30$368.0m. XBRL concept us-gaap:Assets. 10-Q filed 2025-11-06, accession 0001193125-25-269474.Report this figure330Total assets, FY2025, at 2025-12-31$330.4m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-10, accession 0001193125-26-342348.Report this figure285Total assets, Q1 FY2026, at 2026-03-31$285.4m. XBRL concept us-gaap:Assets. 10-Q filed 2026-05-07, accession 0001193125-26-211873.Report this figure423Total assets, Q2 FY2026, at 2026-06-30$423.1m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-10, accession 0001193125-26-342348.Report this figure
Current liabilities$m33.5Current liabilities, Q3 FY2023, at 2023-09-30$33.5m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2023-11-07, accession 0000950170-23-060339.Report this figure48.5Current liabilities, FY2023, at 2023-12-31$48.5m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2025-02-27, accession 0000950170-25-029002.Report this figure33.0Current liabilities, Q1 FY2024, at 2024-03-31$33.0m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-05-07, accession 0000950170-24-054465.Report this figure37.6Current liabilities, Q2 FY2024, at 2024-06-30$37.6m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-08-06, accession 0000950170-24-091838.Report this figure40.0Current liabilities, Q3 FY2024, at 2024-09-30$40.0m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-11-07, accession 0000950170-24-123459.Report this figure40.7Current liabilities, FY2024, at 2024-12-31$40.7m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2026-02-26, accession 0001193125-26-076551.Report this figure35.3Current liabilities, Q1 FY2025, at 2025-03-31$35.3m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-05-08, accession 0000950170-25-066898.Report this figure43.4Current liabilities, Q2 FY2025, at 2025-06-30$43.4m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-08-07, accession 0000950170-25-104996.Report this figure31.2Current liabilities, Q3 FY2025, at 2025-09-30$31.2m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-11-06, accession 0001193125-25-269474.Report this figure30.2Current liabilities, FY2025, at 2025-12-31$30.2m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-10, accession 0001193125-26-342348.Report this figure24.5Current liabilities, Q1 FY2026, at 2026-03-31$24.5m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-05-07, accession 0001193125-26-211873.Report this figure31.3Current liabilities, Q2 FY2026, at 2026-06-30$31.3m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-10, accession 0001193125-26-342348.Report this figure
Total liabilities$m57.7Total liabilities, Q3 FY2023, at 2023-09-30$57.7m. XBRL concept us-gaap:Liabilities. 10-Q filed 2023-11-07, accession 0000950170-23-060339.Report this figure73.8Total liabilities, FY2023, at 2023-12-31$73.8m. XBRL concept us-gaap:Liabilities. 10-K filed 2025-02-27, accession 0000950170-25-029002.Report this figure57.9Total liabilities, Q1 FY2024, at 2024-03-31$57.9m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-05-07, accession 0000950170-24-054465.Report this figure61.8Total liabilities, Q2 FY2024, at 2024-06-30$61.8m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-08-06, accession 0000950170-24-091838.Report this figure63.9Total liabilities, Q3 FY2024, at 2024-09-30$63.9m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-11-07, accession 0000950170-24-123459.Report this figure64.5Total liabilities, FY2024, at 2024-12-31$64.5m. XBRL concept us-gaap:Liabilities. 10-K filed 2026-02-26, accession 0001193125-26-076551.Report this figure58.9Total liabilities, Q1 FY2025, at 2025-03-31$58.9m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-05-08, accession 0000950170-25-066898.Report this figure66.8Total liabilities, Q2 FY2025, at 2025-06-30$66.8m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-08-07, accession 0000950170-25-104996.Report this figure54.4Total liabilities, Q3 FY2025, at 2025-09-30$54.4m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-11-06, accession 0001193125-25-269474.Report this figure53.2Total liabilities, FY2025, at 2025-12-31$53.2m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-10, accession 0001193125-26-342348.Report this figure47.4Total liabilities, Q1 FY2026, at 2026-03-31$47.4m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-05-07, accession 0001193125-26-211873.Report this figure54.3Total liabilities, Q2 FY2026, at 2026-06-30$54.3m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-10, accession 0001193125-26-342348.Report this figure
Shareholders' equity$m541Shareholders' equity, Q3 FY2023, at 2023-09-30$541.1m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2024-11-07, accession 0000950170-24-123459.Report this figure493Shareholders' equity, FY2023, at 2023-12-31$492.6m. XBRL concept us-gaap:StockholdersEquity. 10-K filed 2026-02-26, accession 0001193125-26-076551.Report this figure442Shareholders' equity, Q1 FY2024, at 2024-03-31$441.5m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-06, accession 0001193125-25-269474.Report this figure385Shareholders' equity, Q2 FY2024, at 2024-06-30$384.6m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-06, accession 0001193125-25-269474.Report this figure330Shareholders' equity, Q3 FY2024, at 2024-09-30$329.8m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-06, accession 0001193125-25-269474.Report this figure463Shareholders' equity, FY2024, at 2024-12-31$463.2m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-10, accession 0001193125-26-342348.Report this figure412Shareholders' equity, Q1 FY2025, at 2025-03-31$412.1m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-10, accession 0001193125-26-342348.Report this figure354Shareholders' equity, Q2 FY2025, at 2025-06-30$354.2m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-10, accession 0001193125-26-342348.Report this figure314Shareholders' equity, Q3 FY2025, at 2025-09-30$313.7m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-06, accession 0001193125-25-269474.Report this figure277Shareholders' equity, FY2025, at 2025-12-31$277.2m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-10, accession 0001193125-26-342348.Report this figure238Shareholders' equity, Q1 FY2026, at 2026-03-31$238.0m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-10, accession 0001193125-26-342348.Report this figure369Shareholders' equity, Q2 FY2026, at 2026-06-30$368.8m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-10, accession 0001193125-26-342348.Report this figure

Cash flow

Operating cash flow−$39.6m, Q2 FY2026
Capital expenditure$8.0k, Q2 FY2026
Rocket Pharmaceuticals, Inc., cash flow, quarterly
Line itemUnitQ3 FY20232023-09-30Q4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Operating cash flow$m(57.1)Operating cash flow, Q3 FY2023, three months to 2023-09-30−$57.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2024-11-07, accession 0000950170-24-123459. Derived: 9-month figure less the 6-month figure.Report this figure(29.3)Operating cash flow, Q4 FY2023, three months to 2023-12-31−$29.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2025-02-27, accession 0000950170-25-029002. Derived: 12-month figure less the 9-month figure.Report this figure(56.9)Operating cash flow, Q1 FY2024, three months to 2024-03-31−$56.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-05-08, accession 0000950170-25-066898.Report this figure(53.8)Operating cash flow, Q2 FY2024, three months to 2024-06-30−$53.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-08-07, accession 0000950170-25-104996. Derived: 6-month figure less the 3-month figure.Report this figure(52.1)Operating cash flow, Q3 FY2024, three months to 2024-09-30−$52.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-06, accession 0001193125-25-269474. Derived: 9-month figure less the 6-month figure.Report this figure(46.9)Operating cash flow, Q4 FY2024, three months to 2024-12-31−$46.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-26, accession 0001193125-26-076551. Derived: 12-month figure less the 9-month figure.Report this figure(55.8)Operating cash flow, Q1 FY2025, three months to 2025-03-31−$55.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-07, accession 0001193125-26-211873.Report this figure(49.0)Operating cash flow, Q2 FY2025, three months to 2025-06-30−$49.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-10, accession 0001193125-26-342348. Derived: 6-month figure less the 3-month figure.Report this figure(50.4)Operating cash flow, Q3 FY2025, three months to 2025-09-30−$50.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-06, accession 0001193125-25-269474. Derived: 9-month figure less the 6-month figure.Report this figure(34.8)Operating cash flow, Q4 FY2025, three months to 2025-12-31−$34.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-26, accession 0001193125-26-076551. Derived: 12-month figure less the 9-month figure.Report this figure(45.4)Operating cash flow, Q1 FY2026, three months to 2026-03-31−$45.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-07, accession 0001193125-26-211873.Report this figure(39.6)Operating cash flow, Q2 FY2026, three months to 2026-06-30−$39.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-10, accession 0001193125-26-342348. Derived: 6-month figure less the 3-month figure.Report this figure
Capital expenditure$m4.7Capital expenditure, Q3 FY2023, three months to 2023-09-30$4.7m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2024-11-07, accession 0000950170-24-123459. Derived: 9-month figure less the 6-month figure.Report this figure4.6Capital expenditure, Q4 FY2023, three months to 2023-12-31$4.6m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2025-02-27, accession 0000950170-25-029002. Derived: 12-month figure less the 9-month figure.Report this figure2.0Capital expenditure, Q1 FY2024, three months to 2024-03-31$2.0m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-05-08, accession 0000950170-25-066898.Report this figure1.9Capital expenditure, Q2 FY2024, three months to 2024-06-30$1.9m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-08-07, accession 0000950170-25-104996. Derived: 6-month figure less the 3-month figure.Report this figure1.6Capital expenditure, Q3 FY2024, three months to 2024-09-30$1.6m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-06, accession 0001193125-25-269474. Derived: 9-month figure less the 6-month figure.Report this figure0.3Capital expenditure, Q4 FY2024, three months to 2024-12-31$309.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-26, accession 0001193125-26-076551. Derived: 12-month figure less the 9-month figure.Report this figure0.4Capital expenditure, Q1 FY2025, three months to 2025-03-31$364.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-07, accession 0001193125-26-211873.Report this figure0.1Capital expenditure, Q2 FY2025, three months to 2025-06-30$50.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-10, accession 0001193125-26-342348. Derived: 6-month figure less the 3-month figure.Report this figure(0.1)Capital expenditure, Q3 FY2025, three months to 2025-09-30−$54.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-06, accession 0001193125-25-269474. Derived: 9-month figure less the 6-month figure.Report this figure0.1Capital expenditure, Q4 FY2025, three months to 2025-12-31$80.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-26, accession 0001193125-26-076551. Derived: 12-month figure less the 9-month figure.Report this figure0.1Capital expenditure, Q1 FY2026, three months to 2026-03-31$93.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-07, accession 0001193125-26-211873.Report this figure0.0Capital expenditure, Q2 FY2026, three months to 2026-06-30$8.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-10, accession 0001193125-26-342348. Derived: 6-month figure less the 3-month figure.Report this figure
Share repurchases$mnot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported

Shares

Diluted shares (weighted)114.51m, Q2 FY2026
Rocket Pharmaceuticals, Inc., shares, quarterly
Line itemUnitQ3 FY20222022-09-30Q1 FY20232023-03-31Q2 FY20232023-06-30Q3 FY20232023-09-30Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q1 FY20262026-03-31Q2 FY20262026-06-30
Diluted shares (weighted)m shares66.2Diluted shares (weighted), Q3 FY2022, three months to 2022-09-3066,215,535 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2023-11-07, accession 0000950170-23-060339.Report this figure79.5Diluted shares (weighted), Q1 FY2023, three months to 2023-03-3179,453,519 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-05-07, accession 0000950170-24-054465.Report this figure80.5Diluted shares (weighted), Q2 FY2023, three months to 2023-06-3080,472,362 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-08-06, accession 0000950170-24-091838.Report this figure82.6Diluted shares (weighted), Q3 FY2023, three months to 2023-09-3082,636,120 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-11-07, accession 0000950170-24-123459.Report this figure93.5Diluted shares (weighted), Q1 FY2024, three months to 2024-03-3193,549,884 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-05-08, accession 0000950170-25-066898.Report this figure93.7Diluted shares (weighted), Q2 FY2024, three months to 2024-06-3093,746,243 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-08-07, accession 0000950170-25-104996.Report this figure94.2Diluted shares (weighted), Q3 FY2024, three months to 2024-09-3094,158,491 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-11-06, accession 0001193125-25-269474.Report this figure110Diluted shares (weighted), Q1 FY2025, three months to 2025-03-31110,093,461 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-07, accession 0001193125-26-211873.Report this figure111Diluted shares (weighted), Q2 FY2025, three months to 2025-06-30111,019,647 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-10, accession 0001193125-26-342348.Report this figure112Diluted shares (weighted), Q3 FY2025, three months to 2025-09-30111,571,136 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-11-06, accession 0001193125-25-269474.Report this figure112Diluted shares (weighted), Q1 FY2026, three months to 2026-03-31112,134,059 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-07, accession 0001193125-26-211873.Report this figure115Diluted shares (weighted), Q2 FY2026, three months to 2026-06-30114,513,964 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-10, accession 0001193125-26-342348.Report this figure

Shares outstanding: 109.77mShares outstanding, period not labelled, at 2026-07-31109,774,597 shares. XBRL concept dei:EntityCommonStockSharesOutstanding. 10-Q filed 2026-08-10, accession 0001193125-26-342348.Report this figure at Jul 31, 2026, from the cover of the 10-Q filed Aug 10, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:36 ET. Listed shows no prices and gives no investment advice.